2 / 51
Page 50
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
E u r o p e a n C o n g r e s s o n
Vaccines & Vaccination
and Gynecologic Oncology
Vaccines & Vaccination and Gynecologic Oncology 2018
O c t o b e r 2 6 - 2 7 , 2 0 1 8
B u d a p e s t , H u n g a r y
HOXB9 as a potential target gene for overcoming
platinum resistance in mucinous ovarian cancer
Dong Hoon Suh
Seoul National University Bundang Hospital, Korea
Dong Hoon Suh, Crit Care Obst & Gyne 2018, Volume: 4
DOI:2471-9803-C1-003
Biography
Dong Hoon Suh is a Clinical Professor of the Department
of Obstetrics and Gynaecology in Seoul National University
Hospital. He is a Gynaecologic Oncology Specialist. He has
graduated from Seoul National University School of Medicine
at 2002 and completed his PhD at the same university,
postgraduate school in 2014. He has published more than 50
papers in reputed journals of his field. He is a Vice Secretary
General of organizing committee of the Asian Society of
Gynecologic Oncology (ASGO) and a Principal Editor of its
official journal, Journal of Gynecologic Oncology. He has
been also deeply involved in other medical journal activities as
a Committee Member for Planning and Evaluation of Korean
Association of Medical Journal Editors, KAMJE.
sdhwcj@naver.comA
lthough ovarian cancer is heterogeneous with various histologic types, current
treatment guidelines aregenerally the same for all histologic types. Expression
of HOX genes in epithelial ovarian cancer (EOC) was known to be histology-
specific. We performed a series of in vitro and in vivo studies to find out a tailored
strategy of inhibiting HOXB9 expression for overcoming platinum resistance in
mucinous EOC. HOXA10 and HOXB9 showed exclusively high expression in
SKOV-3 and RMUG-S, respectively. HOXA10 siRNA treatment made a significant
decrease in cell viability of SKOV-3, but not RMUG-S. By contrast, HOXB9 siRNA
treatment made a significant decrease in cell viability of RMUG-S, but not SKOV-
3. HOXA10 siRNA and HOXB9 siRNA treatments: increased the expression level
of cleaved PARP and caspase-3 in SKOV-3 and RMUG-S, respectively; expression
of vimentin was decreased while expression of E-cadherin was increased; SOX-2,
Nanog, and Oct-4 also decreased in both cell lines after specific siRNA treatment.
When injected with RMUG-Sko HOXB9 and SKOV-3oe HOXB9 in mouse models,
we clearly showed that the tumours from RMUG-Sko HOXB9 grew significantly
slower than those from control. By contrast, the tumours from SKOV-3oe HOXB9
grew significantly faster than those from control. After harvesting, the cells from
the SKOV-3oe HOXB9 were characterized with resistance to cisplatin and higher
expression of vimentin than those form the control. Our findings suggest that
platinum-resistance of mucinous ovarian cancer might be defeated by inhibiting
HOXB9, which could be a target of tailored strategy for overcoming the resistance
to platinum in mucinous EOC.